Core Viewpoint - Kangtuo Medical is a leading enterprise in the domestic neurosurgical implant medical device sector, focusing on the research, production, and sales of Class III implantable medical devices, with strong technical barriers [1] Group 1: Business Performance - In Q3 2025, Kangtuo Medical reported revenue of 251 million yuan, ranking 45th out of 50 in the industry, with the industry leader, Yingke Medical, generating 7.425 billion yuan [2] - The net profit for the same period was 75.91 million yuan, placing the company 25th in the industry, while the top performer, Lepu Medical, achieved 999.6 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kangtuo Medical's debt-to-asset ratio was 12.72%, down from 13.14% year-on-year, significantly lower than the industry average of 23.66%, indicating strong solvency [3] - The gross profit margin for the same period was 78.69%, slightly down from 80.33% year-on-year, but still well above the industry average of 48.78%, reflecting robust profitability [3] Group 3: Executive Compensation - Chairman Hu Liren's salary for 2024 was 323,800 yuan, an increase of 14,600 yuan from 2023 [4] - General Manager Zhu Hailong's salary for 2024 was 1.4491 million yuan, up by 74,800 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 15.30% to 5,879, while the average number of circulating A-shares held per account decreased by 13.27% to 13,800 [5]